Milestone Pharmaceuticals to Present at the Piper Sandler 36th Annual Healthcare Conference
Milestone Pharmaceuticals (Nasdaq: MIST) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. President and CEO Joe Oliveto and Chief Commercial Officer Lorenz Muller will engage in a fireside chat on December 4, 2024, at 10:30 a.m. Eastern Time. The event will feature a live webcast available to conference participants. Interested parties can request access to the fireside chat or schedule meetings with the Milestone team by contacting corporateaccess@psc.com.
Milestone Pharmaceuticals (Nasdaq: MIST) ha annunciato la sua partecipazione alla 36ª Conferenza Sanitaria Annuale di Piper Sandler. Il presidente e CEO Joe Oliveto e il Chief Commercial Officer Lorenz Muller parteciperanno a una chat informale il 4 dicembre 2024, alle 10:30 ora dell'Est. L'evento include una diretta streaming disponibile per i partecipanti alla conferenza. Le parti interessate possono richiedere l'accesso alla chat informale o programmare incontri con il team di Milestone contattando corporateaccess@psc.com.
Milestone Pharmaceuticals (Nasdaq: MIST) ha anunciado su participación en la 36ª Conferencia Anual de Salud de Piper Sandler. El presidente y CEO Joe Oliveto y el Director Comercial Lorenz Muller participarán en una charla informal el 4 de diciembre de 2024, a las 10:30 a.m., hora del Este. El evento contará con una transmisión en vivo disponible para los participantes de la conferencia. Las partes interesadas pueden solicitar acceso a la charla informal o programar reuniones con el equipo de Milestone contactando a corporateaccess@psc.com.
밀스톤 제약 (Nasdaq: MIST)는 파이퍼 샌들러 제36회 연례 의료 회의에 참여한다고 발표했습니다. 사장 겸 CEO 조 올리베토와 상업 책임자 로렌츠 뮬러가 2024년 12월 4일 오전 10시 30분(동부 표준시)에 화제의 대화에 참여할 예정입니다. 이 행사는 회의 참가자들을 위해 생중계될 것입니다. 관심 있는 분들은 화제의 대화에 대한 접근 요청이나 밀스톤 팀과의 회의 일정을 미리 corporateaccess@psc.com으로 문의하여 준비할 수 있습니다.
Milestone Pharmaceuticals (Nasdaq: MIST) a annoncé sa participation à la 36ème Conférence Annuelle sur la Santé de Piper Sandler. Le président et CEO Joe Oliveto ainsi que le directeur commercial Lorenz Muller participeront à une discussion informelle le 4 décembre 2024 à 10h30, heure de l'Est. L'événement comportera une diffusion en direct accessible aux participants de la conférence. Les parties intéressées peuvent demander l'accès à la discussion informelle ou programmer des réunions avec l'équipe de Milestone en contactant corporateaccess@psc.com.
Milestone Pharmaceuticals (Nasdaq: MIST) hat seine Teilnahme an der 36. jährlichen Gesundheitskonferenz von Piper Sandler bekannt gegeben. Präsident und CEO Joe Oliveto sowie Chief Commercial Officer Lorenz Muller werden am 4. Dezember 2024 um 10:30 Uhr Eastern Time an einem Interview teilnehmen. Die Veranstaltung wird einen Live-Stream bieten, der den Konferenzteilnehmern zur Verfügung steht. Interessierte können den Zugang zum Interview beantragen oder Meetings mit dem Milestone-Team unter corporateaccess@psc.com vereinbaren.
- None.
- None.
MONTREAL and CHARLOTTE, N.C., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, and Chief Commercial Officer, Lorenz Muller, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, at 10:30 a.m. Eastern Time.
A live webcast of the fireside chat will be available to conference participants. If you are interested in viewing the fireside chat or meeting with the Milestone team during the conference, email corporateaccess@psc.com.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat episodic attacks associated with PSVT and AFib-RVR.
Contact:
Kim Fox,
Vice President, Communications,
kfox@milestonepharma.com
Investor Relations
Chris Calabrese, ccalabrese@lifesciadvisors.com
Kevin Gardner, kgardner@lifesciadvisors.com
FAQ
When is Milestone Pharmaceuticals (MIST) presenting at the Piper Sandler Healthcare Conference?
Who will represent Milestone Pharmaceuticals (MIST) at the Piper Sandler Conference?
How can investors access Milestone Pharmaceuticals' (MIST) presentation at the Piper Sandler Conference?
What type of presentation will Milestone Pharmaceuticals (MIST) give at the Piper Sandler Conference?
